Revista Española de Cardiología (English Edition) Revista Española de Cardiología (English Edition)
Rev Esp Cardiol. 2007;60:1242-9 - Vol. 60 Num.12

Rosuvastatin and Metformin Decrease Inflammation and Oxidative Stress in Patients With Hypertension and Dyslipidemia

Anel Gómez-García a, Gloria Martínez Torres b, Luz E Ortega-Pierres c, Ernesto Rodríguez-Ayala b, Cleto Álvarez-Aguilar d

a Centro de Investigación Biomédica de Michoacán, Instituto Mexicano del Seguro Social, Morelia, Michoacán, México
b Unidad de Investigación en Epidemiología Clínica, Hospital General Regional No. 1, Instituto Mexicano del Seguro Social, Morelia, Michoacán, México
c Facultad de Ciencias Médicas y Biológicas Dr. Ignacio Chávez, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, México
d Unidad de Investigación Médica en Enfermedades Nefrológicas, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México DF, México

Keywords

Oxidative stress. Inflammation. Drugs. Pleiotropic effects. Cardiovascular risk.

Abstract

Introduction and objectives. Both hypertension and dyslipidemia raise the risk of cardiovascular disease because they have proinflammatory effects and increase oxidative stress. The aim of this study was to evaluate the effects of rosuvastatin and metformin on inflammation and oxidative stress in patients with hypertension and dyslipidemia. Methods. This open parallel-group clinical study involved 48 patients with hypertension and dyslipidemia. Of these, 16 were treated with rosuvastatin, 10 mg/day, while 16 received metformin, 1700 mg/day, and the 14 in the control group received starch placebo, 10 mg/day. The following variables were recorded during the study: age, weight, body mass index, blood pressure, glucose, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNFα), glutathione reductase (GSH), glutathione peroxidase (GPx), and superoxide dismutase (SOD). Results. Administration of 10 mg/day of rosuvastatin decreased total cholesterol by 41.7%, LDL cholesterol by 63.0%, and triglycerides by 10.7%, and increased HDL cholesterol by 6.3%. Pharmacological treatment with either rosuvastatin or metformin lead to reductions in IL-6, TNFα, GSH and GPx levels and an increase in the SOD level, and there were significant interactions between the two treatment groups for these variables. Conclusions. Rosuvastatin improved the lipid profile. Moreover, both rosuvastatin and metformin reduced inflammation and oxidative stress. These results demonstrate the presence of an additional cardioprotective effect, which may result from a direct mechanism of action or be a pleiotropic effect. Further long-term studies are required to determine whether rosuvastatin or metformin can be used to decrease the cardiovascular risk resulting from oxidative stress and inflammation.

1885-5857/© 2007 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved

Cookies
x
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.
Cookies policy
x
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.